SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 153.78 |
| Enterprise Value ($M) | 149.08 |
| Book Value ($M) | -12.59 |
| Book Value / Share | -0.28 |
| Price / Book | -12.21 |
| NCAV ($M) | -12.59 |
| NCAV / Share | -0.28 |
| Price / NCAV | -12.21 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -20.95 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.29 |
| Current Ratio | 0.29 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 5.18 |
| Assets | 5.18 |
| Liabilities | 17.77 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 9.99 | 68.42 | |
| 13D/A | Fortress Biotech, Inc. | 9.80 | 3.41 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 177,332 | 822,441 | 21.56 | |
| 93,566 | 468,213 | 19.98 | |
| 147,120 | 545,257 | 26.98 | |
| 109,222 | 356,439 | 30.64 | |
| 235,842 | 754,505 | 31.26 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CELZ – Creative Medical Technology Holdings, Inc. | CGEN – Compugen Ltd. |
| CING – Cingulate Inc. | CLDX – Celldex Therapeutics, Inc. |
| CLNN – Clene Inc. |
Financial data and stock pages provided by
Fintel.io